SGLT‐2 inhibitors can be initiated for kidney protection above an eGFR >20 mL/min/1.73m2, however, if the GFR is below 45 and further glucose lowering is required adding another class of medications to optimise diabetes control is recommended. This evidence concerns the gene SLC5A2 and diabetes mellitus.